# Strategy Inc: financial statements, quarterly MSTR · Nasdaq · CIK 1050446 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mstr.md) · [Financials](/companies/mstr/financials.md) · [Filings](/companies/mstr/filings.md) · [Insiders](/companies/mstr/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mstr/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [0.1](/filings/0000950170-24-119263.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0000950170-25-063536.md) | [0.1](/filings/0000950170-25-102209.md) | [0.1](/filings/0001193125-25-262568.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0001050446-26-000031.md) | [0.1](/filings/0001050446-26-000044.md) | [0.1](/filings/0001193125-25-262568.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0001050446-26-000031.md) | [0.1](/filings/0001050446-26-000044.md) | | Cost of revenue | $bn | [0.0](/filings/0000950170-24-119263.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0000950170-25-063536.md) | [0.0](/filings/0000950170-25-102209.md) | [0.0](/filings/0001193125-25-262568.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | [0.0](/filings/0001193125-25-262568.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | | Gross profit | $bn | [0.1](/filings/0000950170-24-119263.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0000950170-25-063536.md) | [0.1](/filings/0000950170-25-102209.md) | [0.1](/filings/0001193125-25-262568.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0001050446-26-000031.md) | [0.1](/filings/0001050446-26-000044.md) | [0.1](/filings/0001193125-25-262568.md) | [0.1 d](/filings/0001050446-26-000020.md) | [0.1](/filings/0001050446-26-000031.md) | [0.1](/filings/0001050446-26-000044.md) | | Research and development | $bn | [0.0](/filings/0000950170-24-119263.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0000950170-25-063536.md) | [0.0](/filings/0000950170-25-102209.md) | [0.0](/filings/0001193125-25-262568.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | [0.0](/filings/0001193125-25-262568.md) | [0.0 d](/filings/0001050446-26-000020.md) | [0.0](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | | Operating income | $bn | [(0.0)](/filings/0000950170-24-119263.md) | [(0.0) d](/filings/0001050446-26-000020.md) | [(0.2)](/filings/0000950170-25-063536.md) | [(0.2)](/filings/0000950170-25-102209.md) | [(0.4)](/filings/0001193125-25-262568.md) | [(1.0) d](/filings/0001050446-26-000020.md) | [(5.9)](/filings/0001050446-26-000031.md) | [14.0](/filings/0001050446-26-000044.md) | [3.9](/filings/0001193125-25-262568.md) | [(17.4) d](/filings/0001050446-26-000020.md) | [(14.5)](/filings/0001050446-26-000031.md) | [(8.3)](/filings/0001050446-26-000044.md) | | Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001050446-26-000044.md) | not reported | not reported | not reported | [0.0](/filings/0001050446-26-000044.md) | | Income tax | $bn | [0.1](/filings/0000950170-24-119263.md) | [(0.1) d](/filings/0001050446-26-000020.md) | [(0.2)](/filings/0000950170-25-063536.md) | [(0.1)](/filings/0000950170-25-102209.md) | [(0.1)](/filings/0001193125-25-262568.md) | [(0.4) d](/filings/0001050446-26-000020.md) | [(1.7)](/filings/0001050446-26-000031.md) | [4.0](/filings/0001050446-26-000044.md) | [1.1](/filings/0001193125-25-262568.md) | [(5.0) d](/filings/0001050446-26-000020.md) | [(1.9)](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | | Net income | $bn | [(0.1)](/filings/0000950170-24-119263.md) | [0.1](/filings/0000950170-24-119263.md) | [(0.1)](/filings/0001193125-25-262568.md) | [(0.1)](/filings/0001193125-25-262568.md) | [(0.3)](/filings/0001193125-25-262568.md) | [(0.7)](/filings/0000950170-25-063536.md) | [(4.2)](/filings/0001050446-26-000031.md) | [10.0](/filings/0001050446-26-000044.md) | [2.8](/filings/0001193125-25-262568.md) | [(12.4) d](/filings/0001050446-26-000020.md) | [(12.5)](/filings/0001050446-26-000031.md) | [(8.2)](/filings/0001050446-26-000044.md) | | Diluted EPS | $ per share | [(1.01)](/filings/0000950170-24-119263.md) | not reported | [(0.31)](/filings/0000950170-25-063536.md) | [(0.57)](/filings/0000950170-25-102209.md) | [(1.72)](/filings/0001193125-25-262568.md) | not reported | [(16.49)](/filings/0001050446-26-000031.md) | [32.60](/filings/0001050446-26-000044.md) | [8.42](/filings/0001193125-25-262568.md) | not reported | [(38.25)](/filings/0001050446-26-000031.md) | [(24.45)](/filings/0001050446-26-000044.md) | | Basic EPS | $ per share | [(1.01)](/filings/0000950170-24-119263.md) | not reported | [(0.31)](/filings/0000950170-25-063536.md) | [(0.57)](/filings/0000950170-25-102209.md) | [(1.72)](/filings/0001193125-25-262568.md) | not reported | [(16.49)](/filings/0001050446-26-000031.md) | [36.23](/filings/0001050446-26-000044.md) | [9.30](/filings/0001193125-25-262568.md) | not reported | [(38.25)](/filings/0001050446-26-000031.md) | [(24.45)](/filings/0001050446-26-000044.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.0](/filings/0000950170-23-057418.md) | [0.0](/filings/0000950170-25-021814.md) | [0.1](/filings/0000950170-24-051230.md) | [0.1](/filings/0000950170-24-091778.md) | [0.0](/filings/0000950170-24-119263.md) | [0.0](/filings/0001050446-26-000020.md) | [0.1](/filings/0000950170-25-063536.md) | [0.1](/filings/0000950170-25-102209.md) | [0.1](/filings/0001193125-25-262568.md) | [2.3](/filings/0001050446-26-000044.md) | [2.2](/filings/0001050446-26-000031.md) | [1.7](/filings/0001050446-26-000044.md) | | Current assets | $bn | [0.2](/filings/0000950170-23-057418.md) | [0.3](/filings/0000950170-25-021814.md) | [0.2](/filings/0000950170-24-051230.md) | [0.2](/filings/0000950170-24-091778.md) | [0.2](/filings/0000950170-24-119263.md) | [0.3](/filings/0001050446-26-000020.md) | [0.2](/filings/0000950170-25-063536.md) | [0.2](/filings/0000950170-25-102209.md) | [0.2](/filings/0001193125-25-262568.md) | [2.6](/filings/0001050446-26-000044.md) | [2.4](/filings/0001050446-26-000031.md) | [2.7](/filings/0001050446-26-000044.md) | | Total assets | $bn | [3.4](/filings/0000950170-23-057418.md) | [4.8](/filings/0001050446-26-000020.md) | [6.4](/filings/0000950170-25-063536.md) | [7.1](/filings/0000950170-25-102209.md) | [8.3](/filings/0001193125-25-262568.md) | [25.8](/filings/0001050446-26-000020.md) | [43.9](/filings/0001050446-26-000031.md) | [64.8](/filings/0001050446-26-000044.md) | [73.6](/filings/0001193125-25-262568.md) | [61.6](/filings/0001050446-26-000044.md) | [54.3](/filings/0001050446-26-000031.md) | [52.6](/filings/0001050446-26-000044.md) | | Current liabilities | $bn | [0.3](/filings/0000950170-23-057418.md) | [0.3](/filings/0000950170-25-021814.md) | [0.3](/filings/0000950170-24-051230.md) | [0.4](/filings/0000950170-24-091778.md) | [0.3](/filings/0000950170-24-119263.md) | [0.4](/filings/0001050446-26-000020.md) | [0.3](/filings/0000950170-25-063536.md) | [0.3](/filings/0000950170-25-102209.md) | [0.3](/filings/0001193125-25-262568.md) | [0.5](/filings/0001050446-26-000044.md) | [0.4](/filings/0001050446-26-000031.md) | [0.5](/filings/0001050446-26-000044.md) | | Total liabilities | $bn | [2.5](/filings/0000950170-23-057418.md) | [2.6](/filings/0000950170-25-021814.md) | [4.0](/filings/0000950170-24-051230.md) | [4.2](/filings/0000950170-24-091778.md) | [4.6](/filings/0000950170-24-119263.md) | [7.6](/filings/0001050446-26-000020.md) | [10.4](/filings/0000950170-25-063536.md) | [14.4](/filings/0000950170-25-102209.md) | [15.5](/filings/0001193125-25-262568.md) | [10.6](/filings/0001050446-26-000044.md) | [8.6](/filings/0001050446-26-000031.md) | [7.2](/filings/0001050446-26-000044.md) | | Long-term debt | $bn | [2.2](/filings/0000950170-23-057418.md) | [2.2](/filings/0000950170-25-021814.md) | [3.6](/filings/0000950170-24-051230.md) | [3.7](/filings/0000950170-24-091778.md) | [4.2](/filings/0000950170-24-119263.md) | [7.2](/filings/0001050446-26-000020.md) | [8.1](/filings/0000950170-25-063536.md) | [8.2](/filings/0000950170-25-102209.md) | [8.2](/filings/0001193125-25-262568.md) | [8.2](/filings/0001050446-26-000044.md) | [8.2](/filings/0001050446-26-000031.md) | [6.7](/filings/0001050446-26-000044.md) | | Current portion of debt | $bn | [0.0](/filings/0000950170-23-057418.md) | [0.0](/filings/0000950170-25-021814.md) | [0.0](/filings/0000950170-24-051230.md) | [0.1](/filings/0000950170-24-091778.md) | [0.0](/filings/0000950170-24-119263.md) | [0.0](/filings/0001050446-26-000020.md) | [0.0](/filings/0000950170-25-063536.md) | [0.0](/filings/0000950170-25-102209.md) | [0.0](/filings/0001193125-25-262568.md) | [0.0](/filings/0001050446-26-000044.md) | [0.0](/filings/0001050446-26-000031.md) | [0.0](/filings/0001050446-26-000044.md) | | Shareholders' equity | $bn | [0.8](/filings/0000950170-24-119263.md) | [2.2](/filings/0001050446-26-000020.md) | [2.4](/filings/0001193125-25-262568.md) | [2.8](/filings/0001193125-25-262568.md) | [3.8](/filings/0001193125-25-262568.md) | [31.0](/filings/0001050446-26-000044.md) | [32.2](/filings/0001050446-26-000044.md) | [47.5](/filings/0001050446-26-000044.md) | [52.3](/filings/0001193125-25-262568.md) | [44.1](/filings/0001050446-26-000044.md) | [36.7](/filings/0001050446-26-000044.md) | [30.9](/filings/0001050446-26-000044.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(7.4) d](/filings/0000950170-24-119263.md) | [1.2 d](/filings/0001050446-26-000020.md) | [28.6](/filings/0000950170-25-063536.md) | [(23.3) d](/filings/0000950170-25-102209.md) | [(41.0) d](/filings/0001193125-25-262568.md) | [(17.3) d](/filings/0001050446-26-000020.md) | [(2.4)](/filings/0001050446-26-000031.md) | [(34.9) d](/filings/0001050446-26-000044.md) | [(8.3) d](/filings/0001193125-25-262568.md) | [(21.6) d](/filings/0001050446-26-000020.md) | [14.0](/filings/0001050446-26-000031.md) | [(4.1) d](/filings/0001050446-26-000044.md) | | Capital expenditure | $m | [1.5 d](/filings/0000950170-24-119263.md) | [0.3 d](/filings/0001050446-26-000020.md) | [1.5](/filings/0000950170-25-063536.md) | [0.7 d](/filings/0000950170-25-102209.md) | [0.4 d](/filings/0001193125-25-262568.md) | [0.3 d](/filings/0001050446-26-000020.md) | [2.7](/filings/0001050446-26-000031.md) | [2.1 d](/filings/0001050446-26-000044.md) | [2.8 d](/filings/0001193125-25-262568.md) | [0.6 d](/filings/0001050446-26-000020.md) | [1.0](/filings/0001050446-26-000031.md) | [1.8 d](/filings/0001050446-26-000044.md) | | Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: not reported - Share repurchases: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [11.3](/filings/0000950170-23-057418.md) | [14.6](/filings/0000950170-24-051230.md) | [16.1](/filings/0000950170-24-091778.md) | [142](/filings/0000950170-24-119263.md) | [172](/filings/0000950170-25-063536.md) | [179](/filings/0000950170-25-102209.md) | [197](/filings/0001193125-25-262568.md) | [256](/filings/0001050446-26-000031.md) | [307](/filings/0001050446-26-000044.md) | [315](/filings/0001193125-25-262568.md) | [334](/filings/0001050446-26-000031.md) | [353](/filings/0001050446-26-000044.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.